Search for: "Apotex, Inc. v. FDA, et al"
Results 1 - 20
of 71
Sort by Relevance
|
Sort by Date
17 Mar 2020, 1:32 pm
(877) 917-5250 Recent FDA Recalls Not all FDA recalls are given press releases or are posted on the FDA recall list on the agency’s website. [read post]
8 Feb 2017, 3:09 am
Shell Oil Company, et al., No. 16-713 BPCIA – Notice of Commercial Marketing: Apotex Inc., et al. v. [read post]
16 Jan 2017, 5:44 pm
Shell Oil Company, et al., No. 16-713 BPCIA – Notice of Commercial Marketing: Apotex Inc., et al. v. [read post]
14 Nov 2016, 9:16 am
R. 50 JMOL motion) BPCIA – Notice of Commercial Marketing: Apotex Inc., et al. v. [read post]
13 Oct 2016, 6:50 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 Sep 2016, 6:03 pm
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
13 Jul 2016, 7:05 am
" Forest Laboratories Inc. et al v. [read post]
28 Jun 2016, 6:41 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
3 Jun 2016, 6:40 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 May 2016, 8:19 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
3 May 2016, 1:42 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 Apr 2016, 9:58 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
1 Apr 2016, 8:22 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
17 Mar 2016, 2:45 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
4 Mar 2016, 12:25 pm
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
11 Apr 2014, 11:29 am
Id. at *12 holding.Analysis on selecting "150 mg" per month DoseRavnA 1996 article by Ravn et al. [read post]
22 Feb 2012, 5:49 pm
Apotex et al. [read post]
7 Sep 2011, 4:22 am
Highlights this week included: US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas) US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book… [read post]
10 Aug 2011, 4:30 am
(Patent Docs) Prezista (Darunavir) – US: Patent infringement complaint filed following a Paragraph IV certification: Tibotec Inc. et al. v. [read post]
